key: cord-1053246-blbt8wci
authors: Kim, Kang‐Hoon; Park, Ye‐Ji; Jang, Hyun‐Jae; Lee, Seung‐Jae; Lee, Soyoung; Yun, Bong‐Sik; Lee, Seung Woong; Rho, Mun‐Chual
title: Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF‐κB and IL‐6/STAT3 axis in acute lung injury model
date: 2020-07-21
journal: Phytother Res
DOI: 10.1002/ptr.6767
sha: 346b3ccd9b1bdd7dbe3fab3ee41884b97284383b
doc_id: 1053246
cord_uid: blbt8wci

Rosa rugosa Thunb., is as a medicinal plant known for anti‐diabetic, and anti‐inflammatory activities. However, the specific active compounds responsible for the individual pharmacological effects of in R. rugosa extract (95% EtOH) remain unknown. Here, we hypothesized that terpenoid structure, the most abundant constituents in R. rugosa extract, are responsible for its anti‐inflammatory activity. We investigated the phytochemical substituents (compounds 1–13) and newly purified 11‐methoxy polisin A, and 13‐methoxy bisaborosaol F using NMR and ESI‐MS and to screened their effects on NO production in LPS‐induced macrophages. Rugosic acid A (RA) induced to ameliorate NO production, iNOS, and pro‐inflammatory cytokines associated with the NF‐κB. And, RA suppressed IL‐6 secretion and IL‐6‐mediated STAT3 activation in LPS‐mediated inflammation. In addition, RA was evaluated in LPS‐mediated acute lung injury (ALI) model similar to acute pneumonia. Our results suggested that RA was suppressed to translocate nuclear NF‐κB and IL‐6‐mediated STAT3 activation. Finally, RA led to amelioration of ALI by decreasing myeloperoxidase (MPO) and inhibiting phosphorylation of NF‐κB and STAT3. Our group originally found that R. rugosa extract had new methoxy compounds and RA may be alternative natural agent for acute pneumonia similar to severe acute respiratory syndrome by coronavirus.

NF-κB and STAT3 signaling mainly had known to regulate several biological interactions; development, proliferation, differentiation as well as cancer and inflammation (He & Karin, 2011) . In perspectives of inflammatory action, NF-κB acts on a family of inducible transcription factors that regulate a lot of genes associated with individual functional processes in inflammation in innate immune cells, including macrophages (Oeckinghaus & Ghosh, 2009 ). In addition, STAT3 is involved in a family of cytoplasmic protein with SH2 (Src Homology-2) domains.

They act as signal messengers and transcription factors and participate in normal cellular response to growth factors and cytokines (Guanizo, Fernando, Garama, & Gough, 2018) . when activate both NF-κB and STAT3 signaling, genes responsible for inflammation including IL-6 (interleukin-6), IL-10 (interleukin-10), , , , IL-1b (interleukin-1b), Tnf-α (tumor necrosis factor-α), and iNOS (inducible nitric oxide synthase) were induced and regulated in pathogenesis of inflammation diseases (Liu et al., 2017; He & Karin, 2011) . Thus, the safe development of inhibitory agents of activation both NF-κB, and STAT3 is crucial for clinical treatment of inflammatory diseases among natural constituents.

In present study, we newly investigated anti-inflammatory effects of R. rugosa extracts (EtOH 95%) and developed effective compounds under inflammatory condition associated with lipopolysaccharides (LPS) and IL-6-mediated inflammation. Although R. rugosa flower extracts (EtOH 50%) and euscaphic acid, derived from R. rugosa root extracts performed anti-inflammatory and effects in previous study (Um, Han, & Lee, 2018) , there were no academic evaluation for information of ingredients and quantitative analysis among R. rugosa extracts. Here, we further studied that anti-inflammatory agents of terpenoid structures (compound 1 to 13) and originally reported the identification of a new compound, 11-methoxy polisin A and 13-methoxy bisaborosaol F from the R. rugosa extracts (EtOH 95%) using spectroscopic data, including nuclear magnetic resonance (NMR) and electrospray ionization mass spectrometry (ESI-MS). In several phytochemical constituents of R. rugosa extracts (EtOH 95%), our group originally reported that rugosic acid A, sesquiterpenoid structure, had anti-inflammatory effects by amelioration of nitric oxide (NO) production and inhibition of nuclear-translocation of NF-κB under LPS-mediated inflammatory conditions in RAW 264.7. In addition, rugosic acid A significantly disturbed IL-6-mediated STAT3 activation under IL-6/STAT3 screening system. Finally, we tested RA-mediated amelioration of inflammation in LPSmediated acute lung injury as an acute pneumonia model, which was similar to severe acute respiratory syndrome by coronavirus such as COVID-19 pneumonia (Zhao et al., 2020; Bernheim et al., 2020) .

Through our results, RA expect to be alternative natural agent and treatment for acute pneumonia similar to COVID-19 pneumonia.

2 | MATERIALS AND METHODS 2.1 | General experimental procedures 1 H, 13 C and 2D NMR spectra were acquired with instruments of a JEOL JNM-ECA 400 and JEOL JNM-ECA 600 instruments (JEOL, Tokyo, Japan) using TMS as an internal standard. Optical rotations were obtained on a Jasco P-2000 polarimeter (Jasco Corp., Tokyo, Japan), and UV spectra were recorded using a SpectraMax M 2 e spec- All fractions and compounds were analyzed using an Agilent 1,260

series HPLC system (Agilent, Santa Clara). were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin sulfate. Cells were maintained at 37 C in humidified air with 5% CO 2 . (Applied Biosystems, Foster City, CA) was used. The qPCR was employed to verify the mRNA expression using a Step-One Plus Real-Time PCR system. To quantify mRNA expression, Taqman mRNA assay was performed according to the manufacturer's protocol (Applied Biosystems) (Bertucci et al., 2019) . PCR amplification was analyzed using the comparative ΔΔCT method.

The whole cell lysate was extracted using Cell Lysis Buffer (Cell Signaling Technology, Beverly, MA). The cytosolic and nuclear extracts were prepared using an NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Immunoblots analysis was performed as previously described method (Jang et al., 2017) . After transfer to nitrocellulose (NC) membrane, the blocking membrane with 5% skimmed milk powder was incubated overnight at 4 C with primary antibody, including anti-p65 NF-κB (1:1000), anti-IκBα (1:1000), anti-iNOS (1:1000), antilamin B (1:1000), and anti-β-actin antibodies (Cell Signaling Technology, Beverly, MA). The membranes were then incubated with a horseradish peroxide-conjugated anti-rabbit secondary antibody (1:5000) at room temperature. The band densities were calculated with Quantity One software (Bio-Rad Laboratories, Hercules, CA). 

Hep3B cells stably expressing pSTAT3-Luc were established as described previously (Hwang et al., 2016; Oh et al., 2014) . In brief, Hep3B cells stably expressing pSTAT3-Luc were seeded in 96-well culture plates at 2 × 10 4 cells/well, and cells were treated with samples for 1 hr before stimulation with IL-6 (10 ng/mL) for 12 hr.

Luciferase activity was measured according to the manufacturer's protocol (Promega Corp., Madison, WI).

Female BALB/c mice (6 weeks old) were purchased from Orient Bio bisaborosaol F, E1/E2, 13-methoxy bisaborosaol F (4, 5, 6) (Hashidoko, Tahara, & Mizutani, 1993) , rugosic aicd A, D (7, 8) (Hashidoko et al., 1991) , oleanolic acid acetate (9) (Hichri, Jannet, Cheriaa, Jegham, & Mighri, 2003) , ursolic acid (10) (Seebacher, Simic, Weis, Saf, & Kunert, 2003) , corosolic acid (11) (Hou et al., 2009) , trans-, sis-jacumaric acid (12, 13) (Häberlein & Tschiersch, 1994 16 (H-14, H-15 ) to δ C 137.4 (C-12), 74.1 (C-13), from δ H 2.14 (H-9) to δ C 125.9 (C-11) and correlations from δ H 1.00 (H-10) to δ C 41.5 (C-4), 71.9 (C-8), 42.8 (C-9) confirmed the side chain of the compound 5. (Figure 1c ). The compound 5 was finally identified as 13-methoxy bisaborosaol F. (Figure 1a ).

3.2 | Inhibitory effect of nitric oxide production in R. rugosa extract NO is a major pro-inflammatory mediator, involved in the pathogenesis of inflammation (Sharma, Al-Omran, & Parvathy, 2007) . During an inflammatory response, the large amount of NO formed by the action of iNOS surpasses the standard physiological amount of NO (Xie, Kashiwabara, & Nathan, 1994) . A previous study reported that R. rugosa extracts of 50% EtOH had main active substituents; gallic acid and ellagic acid, and anti-inflammatory effects by inhibiting NF-κB and MAPK activation (Tursun et al., 2016) . However, the efficacy of R. rugosa extracts of 95% EtOH and the specific active compound responsible for the inflammatory effects became unclear. Then, we evaluated NO production in LPS-induced RAW 264.7, a mouse macrophage cell line, upon treatment with R. rugosa of 95% EtOH extract and its terpenoid compounds (Figure 2 ). R. rugosa of 95% EtOH extract dose-dependently decreased NO production under LPS stimulation ( Figure 2a ). In addition, to find active compound of inhibitory effect of NO production, we tested 13 compounds of terpenoid structure derived from R. rugosa of 95% EtOH extract (Figure 2b ). Through screening terpenoid compounds in R. rugosa of 95% EtOH extract, we observed highly inhibitory effect of NO production and selected rugosic acid A, oleanolic acid acetate, and ursolic acid. These results suggested that R. rugosa of 95% EtOH extract had inhibitory effect of NO production similar to dexamethasone, and its major active compounds were rugosic acid A, oleanolic acid acetate, and ursolic acid.

iNOS, which is involved in the production of NO, is a novel signaling molecule associated with the MAPK pathway and NF-κB activity in both microglia and macrophage cells (Tripathi, Tripathi, Kashyap, & Singh, 2007) . Subsequently, pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6 are induced by activating nuclear translocation of NF-κB (Liu et al., 2017) .

To investigate intracellular biological evidence of reduced NO level by rugosic acid A, we evaluated the effect of rugosic acid A on the pro-inflammatory mediators such as iNOS, IL-1β, TNF-α, IL-6, and in LPS-induced macrophages (Figure 2c-g) . In our results, rugosic acid A was newly developed inhibition of iNOS under LPS-induced macrophages based on western blotting (Figure 2c ). The graph described significantly inhibition of iNOS (Figure 2d) . The inhibitory effect of rugosic acid A (30 μM) was similar to that of dexamethasone (positive control, 10 μM). Moreover, we tested proinflammatory cytokines after treatment with rugosic acid A. Rugosic acid A (30 μM) significantly inhibited the pro-inflammatory cytokine mRNA of IL-1β, and TNF-α, and IL-6. Specially, rugosic acid A had the more effective prevention of mRNA of IL-6 than dexamethasone (Figure 2e-g) . The inhibition screening of NO production was evaluated among 13 constituents in R. rugosa extract. NO evaluation performed triplicate test, and results described as Mean ± SE. An unpaired Student's t test was used for statistical analysis. ###p < .001 versus Con. **p < .01, ***p < .001, versus LPS. Con; control, LPS; lipopolysaccharide, Dx; dexamethasone. (c) Rugosic acid Adecreased iNOS expression levels in LPSinduced RAW 264.7 cells. (d) Relative ratio of iNOS versus β-actin were measured using densitometry, and dexamethasone was used as positive control. These graphs represented that rugosic acid A dose-dependently inhibited iNOS at concentration of 1, 10, and 30 μM using Immunoblots analysis. (e-g) The mRNA expression levels of IL-1β, TNF-α, and IL-6 were measured using quantitative real-time PCR experiment, and these proinflammatory cytokines were significantly diminished by rugosic acid A. Cells were pre-incubated for 2 hr with rugosic acid A at concentration of 30 μM, and activated by LPS (1 μg/mL) for 2 hr. Results represent as mean ± SE, and dexamethasone was used as a positive control. ##p < .01, ###p < .001 versus Con, *p < .05, **p < .01, and ***p < .001 versus LPS. Con; control, LPS; lipopolysaccharide, Dx; dexamethasone, RA; rugosic acid. (h) Immunoblots analysis displayed that translocation of NF-κB into nucleus and degradation of cytosolic IκBα were suppressed by rugosic acid (30 μM) in RAW 264.7 cells. (i) Rugosic acid (30 μM) suppressed nuclear translocation of NF-κB. After 2 hr of compound 20 treatment, the cells were fixed and permeabilized. NF-κB (green) was immunostained with rabbit-anti-NF-κB followed by FITC-conjugated secondary antibodies and the nuclei (blue) were stained with DAPI. The results shown were representative of two independent experiments [Colour figure can be viewed at wileyonlinelibrary.com] Subsequently, we evaluated preventive effect of nuclear translocation of NF-κB by pretreatment with rugosic acid A quantitatively and qualitatively (Figure 2h ,i). To determine whether rugosic acid A suppressed the nuclear translocation of NF-κB, we evaluated nuclear NF-κB and cytosolic IκBα using western blotting (Figure 2h) . Immunocytochemistry clearly demonstrated that rugosic acid A reduced the translocation of NF-κB into the nucleus in RAW 264.7 cells (Figure 2i ).

Rugosic acid A remarkably ameliorated to translocate nuclear NF-κB by suppressing the degradation of IκBα, similar to dexamethasone. These results suggested that, rugosic acid A was significant anti-inflammatory compound by inhibition of nuclear translocation of NF-κB among terpenoid structures in R. rugosa extracts (95% EtOH).

To further conduct strong inhibition of IL-6 after rugosic acid treatment in RAW 264.7, we tested to discover potent STAT3 inhibitor among major substituents; rugosic acid (compound 7), oleanolic acid acetate (compound 9), and ursolic acid (compound 10) in R. rugosa extracts under IL-6 mediated STAT3 activation in Hep3B cell line, which was co-transfected with pSTAT3-Luc and pcDNA3.1/Hygro vector (Oh et al., 2014) . Using IL-6/STAT3 screening system of the transfected Hep3B cell line, we already reported that oleanolic acid acetate was major inhibitor of IL-6/STAT3 activation (Hwang et al., 2016) . In previous study, ursolic acid had prevention of hepatic carcinoma by inhibition of STAT3 signaling pathway (Liu, Li, Li, & Lin, 2010) . In this study, we originally observed that rugosic acid significantly inhibited IL-6-mediated STAT3 activation (Figure 3a) . The IC50 value of IL-6/ STAT3 activation was represented on Figure 3b ) has rapidly spread in worldwide and has similar symptom with acute pneumonia accompanied by cytokine storm (Mehta et al., 2020) . If rugosic acid A may ameliorate symptom of acute pneumonia by inhibition of NF-κB and STAT3, it will be alternative treatment with COVID-19 similar to tocilizumab, which is an agent of recombinant humanized anti-human IL-6 receptor monoclonal antibody, and used to cure severe COVID-19 patients by inhibiting IL-6 signaling transduction, before development of vaccine of COVID-19 (Xu et al., 2020) . Firstly, we performed evaluation of myeloperoxidase (MPO) concentration in BALF on ALI model, because MPO was used as biomarker of activation and accumulation of neutrophils in lung tissues and clinical signature of pneumonia patients (Abul et al., 2001) . We observed that pretreatment of rugosic acid A (10 μg/mL) significantly ameliorated LPS-mediated MPO concentration ( Figure 4b ). Subsequently, we evaluated preventive effect of phosphorylation of STAT3 and p65 NF-κB by pretreatment with rugosic acid A using western blotting in lung tissue (Figure 4c ). In our results, the administration of rugosic acid A (10 μg/mL) had significantly inhibition of phosphorylation of STAT3 ( Figure 4d ) and p65 NF-κB ( Figure 4e ) in lung tissues. These results suggested that rugosic acid A ameliorated LPS-mediated ALI by decreasing MPO concentration and inhibiting phosphorylation of STAT3 and p65 NF-κB.

3.6 | Quantitative analysis of rugosic acid A in R. rugosa extracts To investigate yield value of rugosic acid A as an anti-inflammatory agent, we performed quantitative analysis ( Figure 5 ). The sesquiterpenoid structure rugosic acid A was exhibited ( Figure 5a ) and evaluated using calibration curve as a standard (Figure 5b) . In quantitative study, R. rugosa extracts (375.9 g) contained 0.8 mg/g of rugosic acid A (Figure 5c and 2.3 Extraction and isolation).

F I G U R E 4 Effect of rugosic acid A on MPO activity in lung tissues of LPS-stimulated ALI mice. (a) Schematic figure of induction of acute lung injury (ALI) mice. (b) After orally pretreatment with agents: RA 10 μg/kg, RA 1 μg/kg, and DX 5 mg/kg for 24 hr, mice intratracheally were injected with LPS (1 mg/mL, 25 μL). Vehicle group were orally administrated with PBS. The lung myeloperoxidase (MPO) concentration was determined on bronchoalveolar lavage fluid (BALF) after LPS injection. The values are presented as mean ± SE (n = 5 in each group). Multifactor ANOVA with Tukey's multiple comparison was used for statistical analyses; ###p < .001, versus control group. *p < .05, and **p < .01, versus LPS group. (c) Expression of phosphorylated STAT3, p65 NF-κB, total STAT3, total p65 NF-κB and β-actin in lung tissue. (d) Quantitative densitometry analysis of the ratio of phos-STAT3 to total STAT3. (e) Quantitative densitometry analysis of the ratio of phos-p65 NF-κB to total p65 NF-κB. ###p < .001, versus control group. *p < .05, **p < .01 and ***p < .001, versus LPS group [Colour figure can be viewed at wileyonlinelibrary.com]

Our group originally found that rugosic acid A, which has sesquiterpenoid structure has bioactivity responsible for the antiinflammatory activity of R. rugosa extract (EtOH 95%) by inhibition of the nuclear translocation of NF-κB, by reduction of pro-inflammatory mediators such as iNOS, TNF-α, and IL-6. Rugosic acid A significantly showed similar to major STAT3 inhibitory phytochemicals; oleanolic acid acetate and ursolic acid. In addition, our group measured quantitative analysis of rugosic acid A in R. rugosa extract (EtOH 95%). These results indicate that R. rugosa extract and its sesquiterpenoid compound, rugosic acid, may be safe and potential therapeutic agent for inflammatory diseases associated with NF-κB and IL-6/STAT3 signaling.

Levels of IL-8 and myeloperoxidase in the lungs of pneumonia patients

Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection

Tumor-targeting, MicroRNA-silencing porous silicon nanoparticles for ovarian cancer therapy

Rosa rugosa attenuates diabetic oxidative stress in rats with streptozotocininduced diabetes

Antiinflammatory activity of Phyllanthus emblica, Plumbago zeylanica and Cyperus rotundus in acute models of inflammation

5 Quantitative analysis of rugosic acid A in R. rugosa extract. (a) Structure of rugosic acid A. (b) Calibration curve of rugosic aicd A standard

HPLC chromatogram pattern of rugosic acid A in extract from hexan fraction of R.rugosa.; HPLC model: Agilent 1100series (Agilent), column: Phenomenex Luna C18 (5 μm, 4.6 × 250 mm), column temperature: 25 C, mobile phase: (a) H 2 O, (b) ACN, gradient: 0-0, 5-0, 45-100, 65(min)-100(B%)

Anti-inflammatory sesquiterpene lactones from Onopordum illyricum L. (Asteraceae), an Italian medicinal plant

STAT3: a multifaceted oncoprotein

Triterpenoids and flavonoids from Leptospermum scoparium

The phytochemistry of Rosa rugosa

Isolation of four novel carotanoids as possible metabolites of Rugosic acid A in Rosa rugosa leaves

Sesquiterpenoids from Rosa rugosa leaves

NF-κB and STAT3-Key players in liver inflammation and cancer

Antibacterial activities of a few prepared derivatives of oleanolic acid and of other natural triterpenic compounds

Triterpene acids isolated from Lagerstroemia speciosa leaves as alphaglucosidase inhibitors

Study of the UV light conversion of Feruloyl amides from Portulaca oleracea and their inhibitory effect on IL-6-induced STAT3 activation

Anti-inflammatory activity of Eudesmane-type Sesquiterpenoids from Salvia plebeia

Antiinflammatory Terpenoids from the leaves and twigs of Dysoxylum gotadhora

Antiinflammatory activity and acute toxicity of Dodonaea viscosa

In vitro inhibitory effects of cirsiliol on IL-6-induced STAT3 activation through anti-inflammatory activity

NF-κB signaling in inflammation

Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells

COVID-19: Consider cytokine storm syndromes and immunosuppression

The NF-kappaB family of transcription factors and its regulation

Vigna angularis inhibits IL-6-induced cellular signalling and ameliorates collagen-induced arthritis

Complete assignments of 1H and 13C NMR resonances of oleanolic acid, 18α-oleanolic acid, ursolic acid and their 11-oxo derivatives

Role of nitric oxide in inflammatory diseases

Anti-inflammatory potential of Saponins from Aster tataricus via NF-kappaB/MAPK activation

The role of nitric oxide in inflammatory reactions

Anti-Inflammatory Effect of Rosa rugosa Flower Extract in Lipopolysaccharide-Stimulated RAW264.7 Macrophages

Ultrasound-assisted extraction and antioxidant activity of phenolic and flavonoid compounds and ascorbic acid from rugosa rose

Norbisabolane and eremophilane sesquiterpenoids from cultures of the Basidiomycete Polyporus ellisii

Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase

Effective treatment of severe COVID-19 patients with tocilizumab

Tormentic Acid Inhibits IL-1β-Induced Inflammatory Response in Human Osteoarthritic Chondrocytes

Anti-inflammatory triterpenes from the apical bud of Gardenia sootepensis

A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias

Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-κB and IL-6/STAT3 axis in acute lung injury model

This research was supported by a grant from the KRIBB Research Initiative Program (KGS1052012 and KGS1002012).

The authors declare no potential conflict of interest.

https://orcid.org/0000-0003-1025-7363